Twist Bioscience Reports Record Revenues and Improved Financials for FY 2025

Details

The company also saw an improvement in gross margin to 50.7% and a reduction in net loss to $77.7 million, down from $208.7 million in the previous year. The financial results were accompanied by the furnishing of related press releases and financial statements as exhibits.

Items reported

About Twist Bioscience Corporation

Twist Bioscience Corporation is a synthetic biology company that develops and sells DNA-based products for research and commercial applications. Twist Bioscience Corporation’s portfolio includes synthetic genes, gene fragments, oligonucleotide pools, and antibody libraries used in therapeutic discovery, diagnostics, agriculture, industrial biotechnology, and academic research. The company also supports advanced workflows such as targeted next-generation sequencing, CRISPR gene editing, mutagenesis, and DNA data storage. Its proprietary semiconductor-based DNA synthesis platform is designed to produce high-quality synthetic DNA at scale, helping customers move from design to experimentation more efficiently. Twist Bioscience Corporation serves biotechnology, pharmaceutical, industrial, and academic customers across multiple regions, making it an important supplier in the life sciences tools and synthetic biology market.